translational evidence

AI models for pharma and biotech R&D

Pharma and biotech R&D AI should be evaluated as an experiment-capacity allocator: the model earns budget when it changes which targets, molecules, assays, biomarkers or IND/CTA-supporting analyses consume scarce validation slots.